Novartis Lutathera® significantly reduced the risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors.

In the NETTER-2 phase III trial, Lutathera plus octreotide LAR significantly prolonged median PFS to 22.8 months versus 8.5 months with high-dose octreotide LAR in patients with newly diagnosed grade 2 and 3 advanced gastroenteropancreatic neuroendocrine tumors (NET-GEP).

' This is the first positive Phase III trial of a first-line radioligand treatment, and the overall efficacy and safety results are among the most clinically relevant seen to date in this type of advanced cancer, addressing an important unmet need for patients. with newly diagnosed advanced NET-GEP', said Jeff Legos, Global Head of Oncology Development at Novartis.

Copyright (c) 2024 CercleFinance.com. All rights reserved.